Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05400109 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
A Phase 1 study of Non-Hodgkin Lymphoma, sponsored by David Wald.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 3
- Study locations
NCT05400109 is a Phase 1 study of Non-Hodgkin Lymphoma that is active but no longer recruiting, run by David Wald. The registered enrollment target is 21 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05400109, a Phase 1 study of Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by David Wald.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL UF-KURE19 CAR-T cells
Study Locations (3)
Ohio
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center - Cleveland
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-04-26 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05400109
The ClinicalTrials.gov registry entry for NCT05400109 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (86% lower). The listed sponsor is David Wald, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05400109 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Iowa.
Frequently Asked Questions
What is clinical trial NCT05400109 about?
NCT05400109 is a clinical study titled "Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas". This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
What is the current status of trial NCT05400109?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-04-26. Estimated completion is 2026-04-01.
What conditions does trial NCT05400109 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05400109?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), UF-KURE19 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05400109?
This trial is sponsored by David Wald, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05400109 being conducted?
This trial has 3 study locations across Iowa, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.